

Appendix 4 – Biographies for the proposed Board

ANDERS TUV

Anders Tuv is the Managing Director of Radforsk Invest, a life science investment company with a focus on cutting edge immunotherapies and precision medicines. A seasoned entrepreneur and investment expert in the life sciences, Anders has driven strategic growth and value through operations, management, business development, global licensing, M&A, IPOs, trade sales and research collaborations. Anders is a co-founder of Zelluna and was the company's first Chairperson. His leadership extends to previously chairing the boards of Nykode Therapeutics and Oncoimmunity and currently serving on the boards of ARTBIO AS, Nextera AS, OnDosis AB and ClexBio/Nordovo Biosciences AS.

BENT JAKOBSEN

Pioneer in TCR technology. Founded Immunocore in 2008 and served as Chief Scientific Officer and Executive Board Member until 2019. Scientific founder of Adaptimmune and Chief Scientific Officer until 2015. Founded Avidex in 1999 (predecessor company for Adaptimmune and Immunocore) where he served as CSO; Avidex was a spin-out from the University of Oxford to develop novel TCR based drugs. Head of the Immune Receptor Group at the Institute of Molecular Medicine in Oxford from 1993 to July 2000. Previously Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark, and post-doctoral researcher in Cambridge. Visiting professor at University of Oxford. Fellow of the Academy of Medical Sciences

EVA-LOTTA ALLAN

Eva-Lotta has >30 years of cooperate, business development and operational experience from the biotechnology industry. During her five years as Immunocores CBO she raised \$320 million in a series A round and established significant partnerships with top pharmaceutical companies. She was previously at Ablynx, as CBO for seven years participating in taking the company public and completed several strategic partnerships. Before that she was Senior Director Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. Eva-Lotta is currently Non-Executive Chair of Draupnir Bio and Maxion Therapeutics and Non-Executive Director of Almirall (and Chair of the Nomination and Remuneration Committee) and Crescendo Biologics. Previous board appointments include BIA, Aleta Biotherapeutics, Targovax, C4X Discovery, Immunocore, Isconova and Vertex Ltd.

HANS IVAR ROBINSON

Hans Ivar Robinson has 30 years professional experience in the pharmaceutical and biotech industry which includes 15 years with foundation, active development and investments in biotech companies. He has held several leading international positions in pharmaceutical and biotech companies such as AstraZeneca and Pfizer, and several board positions in biotech companies. This include leadership of commercial operations, business development and broad experience in foundation and development of biotech companies from discovery to clinical stages. He has extensive experience working with investors and investment banks including capital raising, mergers, and IPOs. Hans Ivar is co-founder of Zelluna and was chairman of Zelluna for 5 years. He is currently executive chairman and co-founder at Nextera, and non-executive director at Accession Therapeutics. Hans Ivar Robinson is the founder and CEO of Birk Venture and holds a M.Sc. from Norwegian School of Economics (NHH).

CHARLOTTE BERG-SVENDSEN

Charlotte Berg-Svensen has broad professional experience across the life science industry from start-ups and Big Corporates within the biotech, medtech and pharmaceutical sectors. She has held leading international roles and board

positions in life science companies such as Pronova Biopharma ASA, BASF SE and Kappa Biosciences AS, including Chief Legal Officer and VP of Strategic Innovation and IP Management at Pronova and BASF, and Chief Commercial Officer in PreDiagnostics AS. She is currently CEO of Cruda AS and non-executive director at Vitux AS. Charlotte Berg-Svendsen holds a Master of Law (LLM) from the University of Oslo and an MBA from the Norwegian School of Economics (NHH).